title: Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.
abstract: Since renal failure itself creates an immunocompromised situation, malignant tumours in haemodialysis patients are increasing due to the prolonged lifespan of these patients. In treating these patients with anticancer agents, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs with extensive renal excretion. On the other hand, if an anticancer drug is removed significantly by haemodialysis, dosage increase would be required to ensure adequate therapeutic efficacy. We address in this review the clinical pharmacokinetic aspects of antineoplastic therapy, and the application of pharmacokinetic principles to the adjustment of dosage of anticancer agents in haemodialysis patients.
authors.affiliation: Division of Obstetrics and Gynecology, Niigata Prefectural Tokamachi Hospital, Niigata, Japan. mastom@lapis.plala.or.jp
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tomita
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Aoki
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D008297:Male; D008657:Metabolic Clearance Rate; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006435:Renal Dialysis
chemical_list: D000970:Antineoplastic Agents